SERB Pharmaceuticals

What started as Société d’Études et de Recherches Biologiques in the 1950s has transformed into SERB Pharmaceuticals, a dynamic and rapidly growing specialty pharmaceutical company dedicated to emergency care and rare diseases. From its humble beginnings, SERB has expanded significantly, boasting the most comprehensive antidote portfolio globally, which includes crucial medical countermeasures for chemical, biological, radiological, and nuclear (CBRN) threats.

With over 500 dedicated employees, SERB operates in over 18 countries and supplies medicines to more than 100 countries worldwide. This expansion reflects SERB's commitment to improving patient outcomes and enhancing healthcare delivery. The company is not only focused on treating complex and life-threatening conditions but also on maintaining a supportive and responsive relationship with healthcare providers, clinicians, and patient associations. SERB is committed to an end-to-end pharmaceutical model; from research and development to manufacturing and marketing, ensuring that lifesaving treatments are readily available. As they look toward the future, SERB continues to innovate and adapt, responding to the needs of patients and the global healthcare environment with integrity and purpose.